8 news items
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
This release contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN
3 Jun 24
regarding FibroGen's strategy, future plans and prospects, including statements regarding its Gal9 clinical program. These forward-looking statements
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
in multiple EGFR (epidermal growth factor receptor) positive cancers and to determining longer term strategy with our global development partner
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
agent in multiple EGFR (epidermal growth factor receptor) positive cancers and to determining longer term strategy with our global development partner
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
FibroGen's strategy, future plans and prospects, including statements regarding FG-3246, its clinical programs and those of its collaboration partner Fortis
mubhkh
FGEN
6 May 24
. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen's strategy, future
ngwfkadti7c9w42xkmzhlnoqiz2414wiq7smi7ek1eqgw6kzu3i3w604nj4
ABAT
ABIO
ACORQ
3 Apr 24
strategy including a stock buyback program of up to $5 million.
Next.e.GO N.V
bfle6w4tccbvg5r6a 58ydvmj61xtul
FGEN
2 Apr 24
-Looking Statements This release contains forward-looking statements regarding FibroGen's strategy, future plans and prospects
- Prev
- 1
- Next